MD-CPSI
Get Real Health®, a wholly owned subsidiary of healthcare solutions company CPSI (NASDAQ: CPSI), is launching a new solution called TalkWithYourDoc.com. The language-agnostic solution enables providers of all sizes around the globe to continue offering revenue-generating healthcare services while serving patients’ needs during the international COVID-19 pandemic.
TalkWithYourDoc.com supports multiple languages and right to left texts and allows patients to set preferred units and languages. Get Real Health brought the full breadth of its international experience to the development of this solution to make TalkWithYourDoc.com a truly global healthcare tool.
Get Real Health is a global leader in developing patient engagement platforms that transform the healthcare experience for patients and clinicians alike. As an international healthcare company, Get Real Health has deployed other solutions in England, The Netherlands, and Australia. The company also has pilots running in the Middle East and has had demonstration projects in Vietnam and Sweden.
TalkWithYourDoc.com, offered free of charge for the remainder of 2020, is an EHR-agnostic, HIPAA-compliant, secure solution that needs no EHR integration and enables quick provider/patient communication, engagement and data sharing without risk of disease transmission. The robust solution is designed to be user-friendly and operate without dedicated IT resources. A healthcare system, hospital or medical practice can have the solution up and running in hours, not days.
“TalkWithYourDoc.com enables clinicians anywhere in the world to see their patients like they’ve never seen them before,” said Robin Wiener, president of Get Real Health. “This is a secure monitoring tool that can aid a provider in diagnosing a patient. It also connects to patients’ medical devices for a 360-degree view of their conditions.”
This solution includes separate portals for both patients and their providers:
- TalkWithYourDoc.com, also available as an Apple or Android App, allows the patient to fill out a COVID-19 screening survey, complete an initial questionnaire, and provide information about his or her underlying conditions and device readings (such as blood sugar). The patient portal also provides a suite of tools, including health journals, integration with home health devices, and a list of tasks that the provider would like the patient to complete.
- The clinical portal enables the review of a patient’s health profile in preparation for the virtual appointment. It also provides alerts and updates to the clinician following the appointment.
- The initial release can collect five key sets of information provided by the patient that can be used to effectively diagnose and treat the patient remotely. The five data sets include: current medications, chronic conditions, notable procedures the patient has undergone, allergies and a symptom tracker.
“TalkWithYourDoc.com not only helps clinicians respond faster and more efficiently to today’s often-overwhelming COVID-19 workload, but also helps support ongoing health and wellness,” said Wiener. “This is about much more than just talking with patients remotely. This innovative solution is keeping healthcare services flowing in a way that truly delivers excellent medical care, while maintaining vital revenue streams that healthcare organizations need to survive during this difficult time and beyond.”
About Get Real Health
Get Real Health, the newest member of the CPSI family of companies, combines a world of new information from patients, devices and apps with existing clinical data to help individuals and healthcare professionals engage and empower each other. By giving providers and patients the information and tools that they need to work together, we help our customers meet their ever-changing patient engagement needs. Our suite of products helps deliver value-based care, improve outcomes, activate patients, and increase patient loyalty and satisfaction, all while meeting regulatory requirements. Visit: www.getrealhealth.com .
About CPSI
CPSI is a leading provider of healthcare solutions and services for community hospitals, their clinics and post-acute care facilities. Founded in 1979, CPSI is the parent of four companies – Evident, LLC, American HealthTech, Inc., TruBridge, LLC and iNetXperts, Corp. d/b/a Get Real Health. Our combined companies are focused on helping improve the health of the communities we serve, connecting communities for a better patient care experience, and improving the financial operations of our customers. Evident provides comprehensive EHR solutions for community hospitals and their affiliated clinics. American HealthTech is one of the nation’s largest providers of EHR solutions and services for post-acute care facilities. TruBridge focuses on providing business, consulting and managed IT services, along with its complete RCM solution for all care settings. Get Real Health focuses on solutions aimed at improving patient engagement for individuals and healthcare providers. For more information, visit www.cpsi.com .
For more information about this solution, visit www.TalkWithYourDoc.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200331005778/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom